Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Short-chain fatty acid production via fermentation by gut microbiota refers to the **microbial metabolic process** in which certain bacteria in the large intestine ferment indigestible polysaccharides—primarily dietary fiber and resistant starch—to generate short-chain fatty acids (SCFAs), mainly acetate, propionate, and butyrate. This is not a single molecular target such as a receptor or enzyme but rather a collective metabolic activity performed by diverse microbial species. SCFAs are produced at high levels daily in the colon and serve several critical roles: • They are the main energy source for colonocytes—the cells lining the colon—and help maintain intestinal barrier integrity. • They modulate immune responses both locally in the gut and systemically. • They influence host metabolism, including glucose homeostasis and lipid metabolism. • They may affect brain function through direct or indirect mechanisms involving neuroendocrine signaling pathways[1][2]. Alterations in SCFA production have been linked to various diseases including inflammatory conditions, metabolic disorders like type 2 diabetes, cardiovascular diseases, some cancers, and potentially neurological disorders. However, "short-chain fatty acid production via fermentation by gut microbiota" is **not itself a druggable molecular target** such as an enzyme or receptor; rather it describes an important physiological process mediated by many different bacterial enzymes and pathways[1][5]. Therefore: • This entry does **not correspond to a canonical therapeutic target** like an individual protein or receptor. • It should be flagged as incorrect if used as a molecular drug target. If you need information on specific receptors that mediate effects of SCFAs—such as Free Fatty Acid Receptor 2 (FFAR2) or Free Fatty Acid Receptor 3 (FFAR3)—those would be considered valid targets with their own structured entries[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Short-chain fatty acid production via fermentation by gut microbiota (SCFA production (by gut microbiota)).